EBA
UTHR icon

Eagle Bay Advisors’s United Therapeutics UTHR Stock Holding History

Eagle Bay Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-44
Closed -$15.5K – 906
2024
Q4 		$15.5K Hold
44
– – 0.01% 503
2024
Q3 		$15.8K Hold
44
– – 0.01% 682
2024
Q2 		$14K Hold
44
– – 0.01% 500
2024
Q1 		$10.1K Buy
+44
New +$9.93K 0.01% 577

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Eagle Bay Advisors's UTHR Position: Q1 2025 in Review

Eagle Bay Advisors sold out of United Therapeutics (UTHR) in Q1 2025, closing a stake of 44 shares — an estimated $15.5K sold.

Eagle Bay Advisors first reported a position in UTHR in Q1 2024 and held it in 4 quarters. The position peaked at $15.8K in Q3 2024. 671 funds tracked by Wall St. Rank hold UTHR as of Q1 2025.

  • Eagle Bay Advisors reported no remaining United Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Eagle Bay Advisors sold 44 United Therapeutics shares in Q1 2025, an estimated $15.5K.
  • Eagle Bay Advisors first reported a position in United Therapeutics in Q1 2024 and held it in 4 quarters.
  • Eagle Bay Advisors's United Therapeutics position peaked at $15.8K in Q3 2024.
  • 671 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.